EcoDrugPlus

Atpase Na+/k+ Transporting Subunit Alpha 2a

Ensembl ID : ENSCCRG00000060672
Gene Symbol: ATP1A2A
1 Cross references
204 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 2a

Ensembl ID : ENSCCRG00000075101
Gene Symbol: ATP1A2A
1 Cross references
202 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 1a

Ensembl ID : ENSCCRG00000067632
Gene Symbol: ATP1B1A
1 Cross references
148 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 1a

Ensembl ID : ENSCCRG00000061614
Gene Symbol: ATP1B1A
1 Cross references
149 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 1b

Ensembl ID : ENSCCRG00000042777
Gene Symbol: ATP1B1B
1 Cross references
261 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 1b

Ensembl ID : ENSCCRG00000042653
Gene Symbol: ATP1B1B
1 Cross references
262 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 2a

Ensembl ID : ENSCCRG00000073597
Gene Symbol: ATP1B2A
1 Cross references
194 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 2a

Ensembl ID : ENSCCRG00000056822
Gene Symbol: ATP1B2A
1 Cross references
191 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 2b

Ensembl ID : ENSCCRG00000029202
Gene Symbol: ATP1B2B
1 Cross references
193 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 2b

Ensembl ID : ENSCCRG00000046528
Gene Symbol: ATP1B2B
1 Cross references
194 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 3a

Ensembl ID : ENSCCRG00000054067
Gene Symbol: ATP1B3A
1 Cross references
226 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 3a

Ensembl ID : ENSCCRG00000058703
Gene Symbol: ATP1B3A
1 Cross references
226 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).